The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic and Wegovy.

Kathryn Thomas presents the first of two programmes looking at the almost overnight emergence of GLP-1 weight loss medications, such as Ozempic, Wegovy and Mounjaro, and explores their impact. While ...

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a ...

GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has conclu ...

Like so many issues in life, taking a short walk or spin on your bike, can provide some relief when it comes to food noise.

Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...

The number of teens and young adults taking GLP-1 drugs has increased by 594 percent—but scientists are still trying to ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

Today we'll look at six European stocks that could continue outperforming in 2025. Some of these companies are available to ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...